Michael Goettler, Viatris CEO

Vi­a­tris agrees to pay $264M to set­tle EpiPen class ac­tion case

Just as Bio­con signs off on a $3.3 bil­lion buy­out of their shared biosim­i­lars busi­ness, Vi­a­tris’s pend­ing law­suit for its con­tro­ver­sial EpiPen might be no more — if the court signs off on it.

Keep­ing de­tails short, the phar­ma snuck in an an­nounce­ment about its EpiPen prod­uct in its Q4 re­port:

The Com­pa­ny has agreed, sub­ject to ap­proval by the Court, to a $264 mil­lion set­tle­ment, while deny­ing any al­le­ga­tion of wrong­do­ing, to re­solve the EpiPen Au­to-In­jec­tor in­di­rect pur­chas­er class ac­tion cas­es pend­ing in the U.S. Dis­trict Court for the Dis­trict of Kansas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.